The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid steady global demand for consumer healthcare products, Haleon's financial results for the first half of 2026 demonstrated resilient performance. The company reported total revenue of £5,602 million, representing an organic increase of 2.6% compared to the previous year. This growth translated into a significant 12.0% rise in adjusted diluted earnings per share (EPS) to 10.3p, driven by productivity gains and margin expansion across its operations.
To bolster shareholder returns, Haleon declared an interim dividend of 2.4p per share, marking a 9% increase year-over-year. This move is supported by free cash flow generation of £769 million during the first half, up from £734 million in H1 2025 according to analyst data. The company also continues its share buyback program, which contributed to EPS growth by reducing the diluted weighted average share count by 1.6%.
In the markets, HLN.L shares stood at 379.7p at close on July 29, 2026, having traded between a day low of 372.5p and a high of 381.91p. Investors are monitoring the broader economic environment following the Eurozone interest rate decision on July 23, which held rates at 2.4%, providing a stable backdrop for multinational firms managing diverse debt portfolios and international commercial paper issuances.